

Resource Summary Report

Generated by [RRID](#) on Aug 23, 2026

pLX304_zeo_eGFP

RRID:Addgene_160095

Type: Plasmid

Proper Citation

RRID:Addgene_160095

Plasmid Information

URL: <http://www.addgene.org/160095>

Proper Citation: RRID:Addgene_160095

Insert Name: eGFP

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:32371478](#)

Vector Backbone Description: Vector Backbone:pLX304 backbone; Vector Types:Mammalian Expression, Lentiviral; Bacterial Resistance:Ampicillin

Plasmid Name: pLX304_zeo_eGFP

Record Creation Time: 20220422T221906+0000

Record Last Update: 20260815T080838+0000

Ratings and Alerts

No rating or validation information has been found for pLX304_zeo_eGFP.

No alerts have been found for pLX304_zeo_eGFP.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lin CC, et al. (2024) PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications, 15(1), 2287.

Lin CC, et al. (2023) Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Research square.